Skip to main content
Premium Trial:

Request an Annual Quote

SGX and Serono to Collaborate on Kinase and Phosphatase Drugs

NEW YORK, March 23 (GenomeWeb News) - Structural Genomix and Serono will collaborate on developing drugs that target kinases and phosphatases, SGX said today.


Under the agreement, SGX will use its X-ray crystallography-based approach, called Fragments of Active Structures, to generate lead compounds against kinase and phosphatase targets provided by Serono. Geneva, Switzerland-based Serono will develop and commercialize drug candidates resulting from the collaboration.


In return, San Diego-based SGX will receive up to $68 million in upfront and research fees and milestone payments. In addition, it will obtain royalties from sales of drugs.


SGX's FAST approach combines screening of lead-like drug fragments using X-ray crystallography with computational design and chemical synthesis.

The Scan

Guidelines for Ancient DNA Work

More than two dozen researchers have developed new ethical guidelines for conducting ancient DNA research, which they present in Nature.

And Cleared

A UK regulator has cleared former UK Prime Minister David Cameron in concerns he should have registered as a consultant-lobbyist for his work with Illumina, according to the Financial Times.

Suit Over Allegations

The Boston Globe reports that David Sabatini, who was placed on leave from MIT after allegations of sexual harassment, is suing his accuser, the Whitehead Institute, and the institute's director.

Nature Papers on Esophageal Cancer, Origin of Modern Horses, Exome Sequencing of UK Biobank Participants

In Nature this week: genetic and environmental influences of esophageal cancer, domestic horse origin traced to Western Eurasian steppes, and more.